Evolving Treatments of Metastatic CRC: Insights from ASCO 2024 - Episode 8

Fruquintinib for mCRC: Data from the FRESCO & FRESCO-2 Studies

, , , ,

Oncology experts evaluate the influence of fruquintinib on current treatment protocols, drawing insights from the FRESCO and FRESCO-2 clinical studies.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Overview of Molecular Testing and Barriers in mCRC
    EP. 2: Clinical Considerations for 2L Treatment Sequencing in mCRC
    EP. 3: Novel Combination Regimens for 2L mCRC: Insights from ASCO 202
    EP. 4: Exploring Toxicities for Second Line Treatments in mCRC
    EP. 5: Existing Challenges for Patients Receiving 3L+ Therapies in mCRC
    EP. 6: Factors Driving 3L Therapeutic Selection for mCRC
    EP. 7: Exploring Data Outcomes From the SUNLIGHT Trial
    Now Viewing
    EP. 8: Fruquintinib for mCRC: Data from the FRESCO & FRESCO-2 Studies
    EP. 9: Examining the Evolving 3L Treatment Landscape for mCRC
    EP. 10: Additional Key Takeaways of ASCO 2024 Data in mCR
    EP. 11: Future Outlooks in the Treatment of Metastatic Colorectal Cancer
    1. Briefly comment on the impact of fruquintinib on your current treatment paradigm based on the FRESCO (Li, et al. JAMA, 2018) and FRESCO-2 (Dasari, et al. Lancet, 2023) studies.
      1. How does the MOA compare to regorafenib or other VEGF inhibitors?

    x